Nivolumab: Five-Year Survival for Melanoma, RCC, and NSCLC

​ Five-year overall survival results have now been revealed for nivolumab in advanced melanoma, renal cell carcinoma (RCC), and non-small cell lung cancer (NSCLC). "We report, to our knowledge, the longest combined clinical follow-up for patients with multiple cancer types receiving any anti–PD-L1 drug," the researchers comment in their secondary analysis of data from the phase I CA209-003 trial and expansion cohorts. This trial was the first multidose trial of nivolumab, an immunotherapy drug t...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.